Quick answer: latest quarter results, by ticker or company name

Home / CYDY / Company Profile

CytoDyn Inc

CYDY | Healthcare | OTC
🌐 Website 📊 Reports 📈 Financials
$0.24
-0.01 (-2.83%)

Key Metrics

Market Cap
$304.89M
P/E Ratio
-8.00
EPS
$-0.03
Beta
N/A
Dividend Yield
N/A
ROE
38.07%
Current Ratio
0.10

Company Information

Industry
Biotechnology

About CytoDyn Inc

CytoDyn Inc operates as a clinicalstage biotechnology company The company focuses on developing treatments for multiple therapeutic indications based on leronlimab a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus HIV nonalcoholic steatohepatitis NASH oncology and such as coronavirus disease COVID19 It is also conducting a Phase 1b2 clinical trial with leronlimab in metastatic triplenegative breast cancer The company was formerly known as RexRay Corporation CytoDyn Inc was incorporated in 2002 and is based in Vancouver Washington

Recent Earnings Surprises

Date Actual EPS Estimated EPS Surprise
2022-08-15 $-0.15 $-0.04 284.8%
2022-04-11 $-0.05 $-0.04 25.0%
2022-01-10 $-0.06 $-0.04 43.5%
2021-10-12 $-0.05 $-0.05 +0.0%

Financial Ratios (TTM)

Gross Margin
0.30%
Operating Margin
316.75%
Net Margin
656.88%
ROA
-434.93%
Price to Book
-2.60
Price to Sales
-53.04